BioSpecifics Technologies Corp.
BSTC
BSTC was delisted on the 1st of December, 2020.
0 hedge funds and large institutions have $0 invested in BioSpecifics Technologies Corp. in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $204K → $0 (-$204K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$204K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS AM
Chicago,
Illinois
| – | -$204K | -2,300 | Closed |
|
BSTC Hedge Fund Activity: Q1 2021 in Review
0 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q1 2021, worth a combined $0 — down 100% from $204K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BSTC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS AM, exiting entirely with an estimated $204K sold.
- 0 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q1 2021, down from 1 in Q4 2020.
- Funds reported $0 of BioSpecifics Technologies Corp. stock for Q1 2021, down 100% quarter-over-quarter.
- 0 funds opened new BioSpecifics Technologies Corp. positions in Q1 2021 and 1 closed out, a net change of -1 holder.
- The largest BioSpecifics Technologies Corp. seller in Q1 2021 was UBS AM, an estimated $204K sold.
Based on aggregated 13F filings for Q1 2021.